Radioimmunotherapy of metastatic prostate cancer with177Lu-DOTA-huJ591 anti prostate specific membrane antigen specific monoclonal antibody

Current Radiopharmaceuticals

Volumn 9, Issue 1, 2016, Pages 44-53

  Vallabhajosula, Shankar ^a   Nikolopoulou, Anastasia ^a   Jhanwar, Yuliya S ^a   Kaur, Gurveen ^a   Tagawa, Scott T ^a   Nanus, David M ^a   Bander, Neil H ^a   Goldsmith, Stanley J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

177Lu DOTA huJ591 mAb; Castaration resistant prostate cancer (CRPC); Prostate specific membrane antigen (PSMA); Radioimmunotherapy (RIT)

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; LUTETIUM 177; MONOCLONAL ANTIBODY J591; PREDNISONE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOPHARMACEUTICAL AGENT; TETRAXETAN MONOCLONAL ANTIBODY J591 LU 177; UNCLASSIFIED DRUG; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; J591 MONOCLONAL ANTIBODY; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; RADIOISOTOPE; SINGLE HETEROCYCLIC RINGS;

ANTIGEN EXPRESSION; ARTICLE; BONE MARROW SUPPRESSION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; DOSIMETRY; DRUG CONJUGATION; DRUG DOSE ESCALATION; HUMAN; ISOTOPE LABELING; MAXIMUM TOLERATED DOSE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG SCREENING; MALE; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; GLUTAMATE CARBOXYPEPTIDASE II; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; MALE; MAXIMUM TOLERATED DOSE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOISOTOPES; RADIOPHARMACEUTICALS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84949808103     PISSN: 18744710     EISSN: 18744729     Source Type: Journal    
DOI: 10.2174/1874471008666150313114005     Document Type: Article

References (50)

1. Siegel, R.; Ma, J.; Zou, Z.; Jemal, J. Cancer statistics 2014. CA. Cancer. J. Clin., 2014, 64, 9-29.
2. DeVita V.T.; Lawrence T.S.; Rosenberg S.A. Cancer: principles and practice of oncology: annual advances in oncology. Philadelphia, USA, Wolters Kluwer/Lippincott Williams & Wilkins Health; 2010.
3. Zelefsky, M.J.; Eastham, J.A.; Sartor, O.; Cancer of the prostate. 9th ed. In: DeVita, V.T.; Lawrence, T.S.; Rosenberg, S.A., Ed. Devita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology, Lippincott Williams and Wilkins, Philadelphia, USA, 2011, pp. 1220-1262.
4. Waldmann, T.A. Immunotherapy: past, present and future. Nat. Med., 2003, 9, 3, 269-277.
5. Reichert, J.M. Marketed therapeutic antibodies compendium. mABs, 2012, 4, 3, 413-415.
6. Bander, N.H.; Nanus, D.M.; Milowsky, M.I.; Kostakoglu, L.; Vallabahajosula, S.; Goldsmith, S.J. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin. Oncol., 2003, 30, 667-677.
7. Horoszewicz J.S.; Kawinski E.; Murphy G.P. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res., 1987, 7, 927-935.
8. Israeli, R.S.; Powell, C.T.; Corr, J.G.; Fair, W.R.; Heston, W.D. Expression of the prostate-specific membrane antigen. Cancer Res., 1994, 54, 1807-1811.
9. Carter, R.E.; Feldman, A.R.; Coyle, J.T. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc. Natl. Acad. Sci. USA, 1996, 93, 2, 749-753.
10. Chang, S.S. Overview of Prostate-specific membrane antigen. Rev. Url., 2004, 6, S10, S13-S18.
11. Grauer, L.S.; Lawler, K.D.; Marignac, J.L.; Kumar A.; Goel A.S.; Wolfert, R.L. Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line. Cancer Res., 1998, 58, 4787-4789.
12. Wright, G.L. Jr., Haley, C.; Beckett, M.L.; Schellhammer, P.F. Expression of prostate-specific membrane antigen (PSMA) in normal, benign and malignant prostate tissues. Urol. Oncol., 1995, 1, 18-28.
13. Wright, L. Jr, Grob, B.; Haley, C.; Grossman, K.; Newhall K.; Petrylak, D.; Troyer, J.; Konchuba, A.; Schellhammer, P.F.; Moriarty, R. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology, 1998, 48, 326-334.
14. Sweat, S.D.; Pacelli, A.; Murphy, G.P.; Bostwick, D.G. Prostatespecific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology, 1998, 52, 637-640.
15. Troyer, J.K.; Beckett, M.L.; Wright, G.L. Jr. Location of prostatespecific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate, 1997, 30, 232-242.
16. Rosenthal, S.A.; Haseman, M.K.; Polascik, T.J.; Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer. Tech. Urol., 2001, 7(1), 27-37.
17. Liu, H.; Rajasekaran, A.K.; Moy, P.; Xia, Y.; Kim, S.; Navaro, V.; Bander, N.H. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res., 1998, 58, 4055-4060.
18. Liu, H.; Moy, P.; Kim, S.; Xia, Y.; Rajasekaran, A.; Navarro, V.; Knudsen, B.; Bander, N.H. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res., 1997, 57, 3629-3634.
19. Smith-Jones, P.M.; Vallabahajosula, S.; Goldsmith, S.J.; Navarro, V.; Hunter, C.J.; Bastidas, D.; Bander, N.H. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. Cancer. Res., 2000, 60, 5237-5243.
20. Hamilton, A.; King, S.; Liu, H.; Moy, P.; Bander, N.H.; Carr, F. A novel humanized antibody against prostate specific membrane antigen (PSMA) for in vivo targeting and therapy. Proc. Am. Assoc. Cancer Res., 1998, 39, 440.
21. Lewis, M.R.; Raubitschek, A.; Shively, J.E. A facile, water-soluble method for modification of proteins with DOTA: Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates. Bioconjug. Chem., 1994, 5, 565-576.
22. Konishi, S.; Hamacher, K.A.; Vallabhajosula, S.; Kothari, P.; Bastidas, D.; Bander, N.H.; Goldsmith, S.J. Determination of immunoreactive fraction of radiolabeled mAbs: what is an appropriate method? Cancer Biother. Radiopharmma., 2004, 19, 706-715.
23. Smith-Jones, P.M.; Vallabhajosula, S.; St Omer, S.; Navarro, V.; Goldsmith, S.J.; Bander, N.H.; 177Lu-DOTA-HuJ591: A new radiolabeled monoclonal antibody (mAb) for targeted therapy of prostate cancer. J. Label. Compds. Radiopharm., 2001, 44, S1, 90-92.
24. Smith-Jones, P.M.; Vallabhajosula, S.; Navarro, V.; Bastidas, D.; Goldsmith, S.J.; Bander, N.H. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J. Nucl. Med., 2003, 44, 610-617.
25. Vallabhajosula, S.; Kothari, P.A.; Konishi, S.; Hamacher, K.A.; Goldsmith, S.J.; Bander, N.H. Radiolabeled J591 antibody specific to prostate specific membrane antigen (PSMA): comparison of Indium-111, Yttrium-90 and Lutetium-177. J. Label. Radiopharma. Compounds., 2003, page numbers!!
26. Vallabhajosula, S.; Smith-Jones, P.M.; Navarro, V.; Goldsmith, S.J.; Bander, N.H. Radioimmunotherapy of Prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen: Studies in nude mice. The Prostate, 2004, 58, 145-155.
27. Yao, D.; Trabulsi, E.J.; Kostakoglu, L.; Vallabhajosula, S.; Joyce, M.A.; Nanus, D.M.; Milowsky, M.; Liu, H.; Goldsmith, S.J.; The utility of monoclonal antibodies in the imaging of prostate cancer. Sem. Urol. Onc., 2002, 20, 211-218.
28. Bander, N.H.; Nanus, D.M.; Milowsky, M.I.; Kostakoglu, L.; Vallabahajosula, S.; Goldsmith, S.J. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin. Oncol., 2003, 30, 667-676.
29. Bander, N.H.; Trabulsi, E.J.; Kostakoglu, L.; Yao, D.; Vallabhajosula, S.; Smith-Jones, P.; Goldsmith, N.H. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J. Urol., 2003, 170, 1717-1721.
30. Nanus, D.; Milowsky, M.I.; Kostakoglu, L.; Smith-Jones, P.M.; Vallabahajosula, S.; Goldsmith, S.J.; Bander, N.H. Clinical use of Monoclonal Antibody HuJ591 Therapy: Targeting Prostate Specific Membrane Antigen. J. Urol., 2003, 170, S84-S89.
31. Bander, N.H.; Milowsky, M.I.; Nanus, D.M.; Kostakoglu, L.; Vallabhajosula, S.; Goldsmith, S.J. Phase I trial of 177lutetiumlabeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J. Clin. Oncol., 2005, 23, 4591-4601.
32. Vallabhajosula, S.; Kuji, I.; Hamacher, K.A.; Konishi, S.; Kostakoglu, L.; Kothari, P.A.; Milowski, M.I.; Nanus, D.M.; Bander, N.H.; Goldsmith, S.J. Pharmacokinetics and biodistribution of 111In-and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu? J. Nucl. Med., 2005, 46, 634-641.
33. Vallabhajosula, S.; Goldsmith, S.J.; Hamacher, K.A.; Kostakoglu, L.; Konishi, S.; Milowski, M.I.; Nanus, D.M.; Bander, N.H. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y-and 177Lu-J591 antibodies specific for prostate-specific membrane antigen. J. Nucl. Med., 2005, 46, 850-858.
34. Vallabhajosula, S.; Goldsmith, S.J.; Kostakoglu, L.; Milowsky, M.I.; Nanus, D.M.; Bander, N.H. Radioimmunotherapy of Prostate Cancer Using 90Y-and 177Lu-Labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clin. Cancer. Res., 2005, 11, 7195s-7200s.
35. David, K.A.; Milowsky, M.I.; Kostakoglu, L.; Vallabhajosula, S.; Goldsmith, S.J Nanus, D.M.; Bander, N.H. Clinical utility of radio labeled monoclonal antibodies in prostate cancer. Clin. Genitourin. Cancer, 2006, 4, 249-56.
36. Tagawa, S.T.; Beltran, H.; Vallabhajosula, S.; Goldsmith, S.J.; Osborne, J.; Matulich, D.; Petrillo, K.; Parmar, S.; Nanus, D.M.; Bander, N.H. Anti-Prostate Specific Membrane Antigen-based Radioimmunotherapy for Prostate Cancer. Cancer, 2010, 116, S4, 1075-83.
37. Tagawa, S.T.; Milowsky, M.I.; Morris, M.; Vallabhajosula, S.; Christos, P.; Akhtar, N.H.; Osborne, J.; Goldsmith, S.J.; Larson, S.; Pandit-Taskar, N.; Scher, H.I.; Bander, N.H.; Nanus, D.M. Phase II study of lutetium-177 labeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 for metastatic castrationresistant prostate cancer. Clin. Cancer. Res., 2013, 19, 18, 5182-5191.
38. Tagawa, S.T.; Akhtar, N.H.; Nikolopoulou, A.; Kaur, G.; Robinson, B.; Kahn, R.; Vallabhajosula, S.; Goldsmith, S.J.; Nanus, D.M.; Bander, N.H. Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody J591 in men with metastatic castrationresistant prostate cancer. Front. Oncol., 2013, 3, 214, 1-6.
39. DeNardo, S.J.; Kramer, E.L.; O’Donnell, R.T.; Richman, C.M.; Salako, Q.A.; Shen, S.; Noz, M.; Glenn, S.D.; Ceriani, R.L.; DeNardo, G.L. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial. J. Nucl. Med., 1997, 38, 1180-1185.
40. Lovqvist, A.; Humm, J.L.; Sheikh, A.; Finn, R.D.; Koziorowski, J.; Ruan, S.; Pentlow, K.S.; Jungbluth, A.; Welt, S.; Lee, F.T.; Brechbiel, M.W.; Larson, S.M. PET imaging of 86Y-labeled anti-Lewis Y monoclonal antibodies in a nude mouse model: comparison between 86Y and 111In radiometals. J. Nucl. Med,. 2001, 42, 1281-1287.
41. Goel, A.; Augustine, S.; Baranowska-Kortylewicz, J.; Colcher, D.; Booth, B.J.; Pavlinkova, G.; Tempero, M.; Batra, S.K. Singledose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 Singlechain Fvs. Clin. Cancer Res., 2001, 7, 175-184.
42. DeNardo, G.L.; Schlom, J.; Buchsbaum, D.J.; Meredith, R.F.; O'Donoghue, J.A.; Sgouros, G.; Humm, J.L.; DeNardo, S.J. Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer, 2002, 94, 1332-1348.
43. Illidge, T.M.1.; Mayes, S.; Pettengell, R.; Bates, A.T.; Bayne, M.; Radford, J.A.; Ryder, W.D.; Le Gouill, S.; Jardin, F.; Tipping, J.; Zivanovic, M.; Kraeber-Bodere, F.; Bardies, M.; Bodet-Milin, C.; Malek, E.; Huglo, D.; Morschhauser, F. Fractionated 90Yibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria. J. Clin. Oncol., 2013, 31, 1-8.
44. Ocean, A.J.; Pennington, K.L.; Guarino, M.J.; Sheikh, A.; Bekaii-Saab, T.; Serafini, A.N.; Lee, D, Sung MW, Gulec SA, Goldsmith SJ, Manzone T, Holt M, O'Neil BH, Hall N, Montero AJ, Kauh J.; Gold, D.V.; Horne, H.; Wegener, W.A.; Goldenberg, D.M. Fractionated radioimmunotherapy with 90Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer. A phase1 trial. Cancer, 2012, 15, 5497-5506.
45. Tagawa, S.T.; Vallabhajosula, S.; Osborne, J.R.; Goldsmith, S.J.; Petrillo, K.; Tyrell, L.; Dhillon, G.S.; Beltran, H.; Bander, N.H.; Nanus, D.M. Phase I trial of fractionated-dose 177lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients (pts) with metastatic castration-resistant prostate cancer (metastatic CRPC). J. Clin.Oncol., 2010, 29, 15, S2010-4667 (abstract).
46. Tagawa, S.T.; Akhtar, N.H.; Nikolopoulou, A.; Vallabhajosula, S.; Osborne, J.R.; Beltran, H.; Kahn, R.; Goldsmith, S.J.; Nanus, D.M.; Bander, N.H. Phase I trial of fractionated-dose 177Lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer (CRPC) [Tagawa 2013 ECCO] abstract
47. Petrylak, D.P. New paradigms for advanced prostate cancer. Rev. Urol., 2007, 9, S2, S3-S12.
48. Kumar, P. A New Paradigm for the treatment of high-risk prostate cancer: radiosensitization with docetaxel. Rev Urol., 2003, 5(Suppl 3):, S71-S77.
49. Alcorn, S.; Walker, A.J.; Gandhi, N.; Narang A, Wild AT, Hales, R.K, Herman, J.M.; Song, D.Y.; Deweese, T.L.; Antonarakis, E.S.; Tran, P.T. Molecularly targeted agents as radiosensitizers in cancer therapy-focus on prostate cancer. Int. J. Mol. Sci., 2013, 14, 14800-14832.
50. Tagawa, S.T.; Whang, Y.E.; Kaur, K.; Vallabhajosula, S.; Paul, J.C.; Nikolopoulou, A.; Jhanwar, Y.; Sheikh, A.; Ireland, A.; Garcias-Espana, C.; Goldsmith, S.J.; Beltran, H.; Bander, N.H.; Nanu, D.M. Phase I trial of docetaxel/ prednisone plus fractionated dose radiolabeled anti-prostate specific membrane antigen (PSMA) monoclonal antibody 177lu-J591 in patients with metastatic, castration-resistant prostate cancer (mCRPC). Paper presented at the ASCO annual meeting May-June, 2014.